Switch from Ritonavir to Indinavir in Combination Therapy for HIV‐1–Infected Children | Zendy

Stephen I. Pelton | Zendy; Kenneth Stanley | Zendy; Ram Yogev | Zendy; Courtney V. Fletcher | Zendy; Kenneth McIntosh | Zendy; Andrew Wiznia | Zendy; Sharon Nachman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Switch from Ritonavir to Indinavir in Combination Therapy for HIV‐1–Infected Children

Author(s) -

Stephen I. Pelton,

Kenneth Stanley,

Ram Yogev,

Courtney V. Fletcher,

Kenneth McIntosh,

Andrew Wiznia,

Sharon Nachman

Publication year - 2005

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/428833

Subject(s) - indinavir , ritonavir , medicine , regimen , stavudine , lamivudine , protease inhibitor (pharmacology) , lopinavir , pharmacology , zidovudine , gastroenterology , viral load , virology , viral disease , human immunodeficiency virus (hiv) , virus , antiretroviral therapy , hepatitis b virus

Protease inhibitors are an effective component of combination antiretroviral treatment for children infected with human immunodeficiency virus 1 (HIV-1), but tolerance or toxicity issues sometimes require an alternative therapeutic strategy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research